Clenbutaplex 40 mcg is an oral tablet containing Clenbuterol Hydrochloride, manufactured by Axiolabs and supplied as 40 mcg per tablet in 100-tablet packages.
Clenbutaplex 40 mcg contains clenbuterol hydrochloride, a selective β2-adrenergic receptor agonist with bronchodilator and thermogenic properties. It is approved in some countries for the treatment of bronchial asthma and chronic obstructive bronchitis, but it is not approved by the FDA for any human indication in the United States. The standard clinical oral dose in jurisdictions where it is approved is 40 mcg once daily or divided.
In bodybuilding and performance-enhancement contexts, clenbuterol is widely referenced for its fat-burning and potential anabolic effects. A 2026 randomized controlled trial in healthy adults found that 80 mcg/day of clenbuterol during resistance training significantly increased lean mass and muscle protein synthesis compared to placebo. However, clenbuterol is classified by WADA as an **S1.2 Other Anabolic Agent** and is prohibited at all times in sport. Non-medical use falls outside approved indications and carries significant cardiovascular risk.
Clenbuterol's mechanism involves β2-adrenoceptor activation, which relaxes bronchial smooth muscle and increases metabolic rate and lipolysis. Documented adverse effects include tachycardia, tremor, hypokalemia, and cardiac arrhythmias. The product's laboratory report shows a measured content of 47.89 mcg per tablet, which is 119.72% of the 40 mcg label claim.
Clenbuterol is a long-acting β2-adrenoceptor agonist with bronchodilator and thermogenic properties. Its research profile spans asthma, body composition, and anti-doping science.
Clenbuterol belongs to the class of selective β2-adrenoceptor agonists, which bind to and activate β2 receptors predominantly found in smooth muscle tissue including the lungs, uterus, and blood vessels. Upon binding, clenbuterol activates intracellular signaling that relaxes smooth muscle, producing bronchodilation.
The pharmacokinetic profile of clenbuterol includes rapid gastrointestinal absorption, with onset of action in 15–20 minutes and peak plasma concentrations at 2–3 hours. The bronchodilator effect persists for 6–8 hours, and the elimination half-life is approximately 35 hours. The molecular weight of clenbuterol hydrochloride is 313.65 g/mol.
At higher doses or in non-medical contexts, clenbuterol's β2-agonist activity produces metabolic effects including increased energy expenditure and fat oxidation. A 2026 randomized controlled trial in healthy adults demonstrated that 80 mcg/day of clenbuterol during 8 weeks of resistance training significantly increased lean mass and induced mTOR phosphorylation in skeletal muscle compared to placebo.
Clenbuterol's defining pharmacological characteristic is its dual action: β2-mediated bronchodilation for respiratory indications and dose-dependent thermogenic/anabolic effects at higher exposures.
Axiolabs offers several compounds referenced in bodybuilding research. T3 (liothyronine) is a thyroid hormone used for metabolic acceleration. Clomiplex (clomiphene) is a selective estrogen receptor modulator for PCT. Arimiplex (anastrozole) is an aromatase inhibitor. Clenbutaplex provides β2-agonist activity for research into thermogenesis and body composition.
Published laboratory reports for Clenbutaplex 40 mcg by Axiolabs are shown below with the test date, measured content and percentage of the product's 40 mcg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
The information below is provided for educational reference only. Clenbuterol is a prescription medicine in jurisdictions where it is approved; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
In jurisdictions where clenbuterol is approved for respiratory indications, the standard oral dose is 40 mcg once daily or divided, with a maximum of 80 mcg/day for severe bronchospasm. In clinical research, a 2026 randomized controlled trial used 80 mcg/day during resistance training. In non-medical bodybuilding contexts, clenbuterol is commonly referenced in escalating protocols starting at 20 mcg/day and titrating up to 120 mcg/day, but these doses are not supported by approved labeling and carry significant cardiovascular risk.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Medical (approved jurisdictions) | 20–40 mcg | Once daily or divided |
| Clinical trial (resistance training) | 80 mcg | Daily |
| Non-medical (not approved) | 20–120 mcg | Titrated per protocol |
Clenbuterol's most common adverse effects include tremor, tachycardia, palpitations, and nervousness. These effects are dose-dependent and may attenuate with continued use. More serious cardiovascular effects including arrhythmias and hypokalemia have been reported. Taurine supplementation and potassium monitoring are commonly referenced in non-medical contexts, though these practices are not supported by clinical guidelines.
Clenbuterol is contraindicated in patients with tachyarrhythmias, hypertrophic obstructive cardiomyopathy, and acute myocardial infarction. Caution is advised in patients with hypertension, hyperthyroidism, and diabetes. Clenbuterol can potentiate the toxicity of digoxin and may interact with β-blockers, tricyclic antidepressants, and drugs that prolong the QT interval.
The information above is for educational reference and does not constitute medical advice. Clenbuterol is prohibited in sport by WADA at all times.
Clenbuterol is not FDA-approved for human use in the United States and is classified as a WADA S1.2 prohibited substance. Medical use requires appropriate diagnosis and clinical supervision.
Clenbuterol is a potent β2-agonist with significant cardiovascular effects. The FDA has not approved clenbuterol for any human indication in the United States. WADA classifies clenbuterol under section S1.2 Other Anabolic Agents, prohibited at all times in- and out-of-competition. Documented adverse events from clenbuterol misuse include tachycardia, hypokalemia, hypophosphatemia, and cardiac complications.
Non-medical use of clenbuterol falls outside approved indications. Clenbuterol is prohibited in sport and subject to anti-doping sanctions. Product purity does not establish that non-medical use is safe or appropriate.
Common adverse reactions reported with clenbuterol include tremor, palpitations, tachycardia, nervousness, headache, dry mouth, and nausea. Rare but serious effects include cardiac arrhythmias, hypokalemia, hyperglycemia, and anaphylactic reactions. In cases of clenbuterol toxicity from misuse, cardiovascular effects including tachycardia and hypokalemia have required hospitalization.
Clenbuterol is contraindicated in patients with thyrotoxicosis, idiopathic hypertrophic subaortic stenosis, tachycardia, tachyarrhythmias, and acute myocardial infarction. Caution is required in patients with hypertension, cardiac arrhythmias, and diabetes mellitus. Clenbuterol should not be used during pregnancy or breastfeeding.
If clenbuterol is used in any context, monitoring of heart rate, blood pressure, and serum potassium may be considered due to the known cardiovascular and electrolyte effects. No standardized monitoring protocol exists for non-medical use. Laboratory testing of the product itself is separate from clinical monitoring of the individual.
Store tablets in a closed container at controlled room temperature, away from excessive heat, moisture, and direct light. Keep out of reach of children. Do not use if the packaging is damaged or if tablets appear discolored.
Clenbutaplex 40 mcg by Axiolabs is supplied through the official distribution chain and shipped with discreet, privacy-focused handling.
The outer shipping package remains discreet, with no external product details. Products are supplied through the official Axiolabs distribution chain.
To verify your Clenbutaplex 40 mcg product, use the security code on the packaging and cross-check it on the official Axiolabs site. A laboratory report dated January 8, 2025 measured the content at 47.89 mcg per tablet, equivalent to 119.72% of the 40 mcg label claim. Original packaging and batch documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve tablet integrity and maintain product stability throughout shelf life.
Store tablets in a closed container at controlled room temperature (15–25°C), protected from excessive heat, moisture, and direct light. Keep the product in its original packaging until use.
Do not use if the packaging is damaged or if tablets appear discolored or degraded. Keep out of reach of children.
Answers to common questions about Clenbutaplex 40 mcg, clenbuterol research, and product details.
Clenbutaplex 40 mcg contains clenbuterol hydrochloride, a β2-adrenergic agonist. In jurisdictions where it is approved, it is used for bronchial asthma and chronic obstructive bronchitis. In non-medical bodybuilding contexts, it is referenced for thermogenic and potential anabolic effects, though this use is not approved.
The approved clinical dose is 20–40 mcg once daily or divided, with a maximum of 80 mcg/day for severe bronchospasm. Clinical research has used 80 mcg/day. Non-medical protocols reference escalation up to 120 mcg/day, but these doses are not approved and carry significant risk.
Clenbuterol is not an anabolic steroid and does not suppress endogenous testosterone production in the same way as AAS. Post-cycle therapy designed for steroid cycles is not applicable. Its mechanism involves β2-adrenoceptor activation, not hormonal suppression of the HPTA.
Clenbuterol binds and activates β2-adrenoceptors, relaxing bronchial smooth muscle and producing bronchodilation. At higher doses, it increases energy expenditure, fat oxidation, and may enhance muscle protein synthesis.
Clenbuterol is rapidly absorbed after oral administration, with onset of action in 15–20 minutes and peak plasma concentrations at 2–3 hours. The bronchodilator effect persists for 6–8 hours. The elimination half-life is approximately 35 hours.
Clenbuterol has demonstrated significant effects on energy expenditure and fat oxidation in clinical research. However, it is not FDA-approved for weight loss, and its cardiovascular risks are well documented. No single fat-burning compound is universally superior.
T3 (liothyronine) is a thyroid hormone that directly increases metabolic rate. Clenbutaplex (clenbuterol) works through β2-adrenoceptor activation to increase thermogenesis and lipolysis. These represent different mechanisms of metabolic acceleration.
Clomiplex (clomiphene) is a selective estrogen receptor modulator used for post-cycle therapy to restore testosterone production. Clenbutaplex (clenbuterol) is a β2-agonist for thermogenic research. Their mechanisms and research applications are entirely different.
40 mcg is the standard clinical dose in jurisdictions where clenbuterol is approved for respiratory indications. The laboratory report for this Clenbutaplex product measured 47.89 mcg per tablet, which is 119.72% of the 40 mcg label claim.
Clenbutaplex 40 mcg by Axiolabs contains 40 mcg of clenbuterol hydrochloride per tablet. It is supplied as 100 tablets per package. A laboratory report dated January 8, 2025 measured the content at 47.89 mcg, equivalent to 119.72% of the label claim.
Yes. A published laboratory report dated January 8, 2025 measured Clenbutaplex 40 mcg at 47.89 mcg per tablet, equivalent to 119.72% of its 40 mcg label claim. The complete report can be viewed in the Lab Reports tab.
Yes. Clenbuterol is classified by WADA as an S1.2 Other Anabolic Agent and is prohibited at all times, both in-competition and out-of-competition. Detection can result in suspensions of 6 months to 2 years.